| Similar Articles |
|---|
 |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note.   |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
December 1, 2008
Brian Orelli |
Obama Can't Save Stem Cell Companies While government-sponsored research on embryonic stem cells might eventually help scientists better understand all stem cells, it's not likely to help the companies right now. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
Reason
July 2005
Ronald Bailey |
Censored Science Speaking out on stem cells: The Washington Post noted that even President Bush's handpicked NIH director, Elias Zerhouni, may not be on board with administration's stem cell policy. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
Salon.com
December 29, 2000
Arthur Allen |
Will Thompson, Bush clash over human embryo research? The HHS nominee supports it, but right-to-lifers want it stopped.... |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Reason
October 2001
Ronald Bailey |
Blastocyst Brouhaha Which human cells count as people? |
Popular Mechanics
November 27, 2007
Alex Hutchinson |
Stem Cells 2.0: Beyond the Hype, Engineers Look to Build Fast Engineers play the important role of making lab bench discoveries reproducible and efficient for use in industry. |
Chemistry World
April 6, 2009
Rebecca Trager |
US funding boost - a threat to EU science? These developments have raised some concern about the possibility of a 'brain drain' from Europe to the US, as these falling barriers have quickly made the region a more appealing destination for researchers. |
Scientific American
March 2006
Sara Beardsley |
Down in Flames Can stem cell research recover from Woo Suk Hwang? |
